Inactive Instrument

Highlights Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Novo Nordisk Completes Acquisition of Forma Therapeutics; Forma Shares to be Delisted	22-10-14	MT
Novo Nordisk Completes Acquisition of Forma Therapeutics	22-10-14	MT
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Forma Therapeutics Holdings, Inc. (NasdaqGM : FMTX) from RA Capital Management, L.P. and others.	22-10-12	CI
Forma Therapeutics Shares Surge on Takeover by Novo Nordisk	22-09-01	DJ
Novo Nordisk to Acquire Forma Therapeutics in $1.1 Billion Deal	22-09-01	MT
Novo Nordisk To Acquire US-based Forma Therapeutics For $1 Billion	22-09-01	MT
Novo Nordisk to Buy Forma Therapeutics for $1.1 Billion	22-09-01	DJ
Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal	22-09-01	RE
Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Forma Therapeutics Holdings, Inc. from RA Capital Management, L.P. and others for approximately $990 million	22-08-31	CI
FORMA THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-05	AQ
Forma Therapeutics Holdings Q2 Net Loss Widens	22-08-05	MT
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
Rigel Pharmaceuticals, Inc. and Forma Therapeutics Holdings, Inc. Announces Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia	22-08-02	CI
FORMA THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-06	AQ
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI
FORMA THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	22-03-01	AQ
Forma Therapeutics Posts Wider Q4 Loss	22-03-01	MT
Forma Therapeutics Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-03-01	CI
Forma Therapeutics Holdings, Inc.'s Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia	21-12-16	CI
Forma Therapeutics Holdings, Inc.’s Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease	21-12-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Forma Therapeutics Holdings, Inc.

Equities

FMTX

US34633R1041

Highlights

Filters